Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,351 | -504 | -3,102 | -2,438 | -1,663 |
| Depreciation Amortization | 5 | 2 | 9 | 7 | 5 |
| Accounts payable and accrued liabilities | -354 | -306 | -418 | -309 | -105 |
| Other Working Capital | -484 | -554 | 473 | 384 | 394 |
| Other Operating Activity | 377 | 317 | 466 | 345 | 127 |
| Operating Cash Flow | $-1,807 | $-1,045 | $-2,572 | $-2,011 | $-1,242 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -168 | -87 | N/A | N/A | N/A |
| Debt Issued | 1,638 | 968 | 2,475 | 2,225 | 1,325 |
| Debt Repayment | -100 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | -283 | N/A | N/A |
| Other Financing Activity | 0 | -100 | 0 | -235 | -153 |
| Financing Cash Flow | $1,370 | $781 | $2,192 | $1,990 | $1,172 |
| Exchange Rate Effect | -1 | -1 | -25 | -1 | -3 |
| Beginning Cash Position | 1,027 | 1,027 | 1,432 | 1,432 | 1,432 |
| End Cash Position | 589 | 763 | 1,027 | 1,410 | 1,359 |
| Net Cash Flow | $-438 | $-264 | $-405 | $-22 | $-73 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,807 | -1,045 | -2,572 | -2,011 | -1,242 |
| Free Cash Flow | -1,807 | -1,045 | -2,572 | -2,011 | -1,242 |